ArticleArchives of toxicology2026
Development of a QSAR model for predicting PPARα activation by PFAS based on human in vitro data of a comprehensive panel of legacy and novel PFAS.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging Nano-Interface Interactions and Organ-Specific Toxicity: A Review of Machine Learning for Nanomaterials Risk Assessment.Molecules (Basel, Switzerland) · 2026Review
- Analysis of transcriptomic alterations induced by 33 different per- and polyfluoroalkyl substances (PFAS) in differentiated HepaRG cells.Archives of toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are a large family of persistent environmental contaminants. Some PFAS are known to bioaccumulate, are frequently detected in human serum, and are associated with several adverse effects on the immune system, the endocrine system, and the liver. PFAS-mediated activation of the peroxisome proliferator-activated receptor alpha (PPARα), which plays a key role in lipid and cholesterol homeostasis, is suggested to be an important molecular initiating event triggering PFAS toxicity. The aim of this study was to evaluate the PPARα activation potential of a diverse panel of 34 PFAS congeners, consisting of both legacy and novel compounds, using a PPARα-dependent transactivation assay in transfected HEK293T cells. The resulting concentration-response data were analyzed using benchmark dose (BMD) modelling to quantify PPARα activation potency. A key finding was that PFAS with a sulfonic acid group showed a lower potency compared to those with a carboxylic group. The most potent activators belonged to the perfluoroalkylether carboxylic acid (PFECA) subgroup. Computational descriptors were generated to characterize each congener, and quantitative structure-activity relationship (QSAR) modelling was applied to relate molecular features to in vitro PPARα activation potency, as expressed by BMD estimates. For prioritization purposes in the context of PFAS hazard characterization, the QSAR model was used to screen about 10,000 PFAS congeners. Of these, roughly 10% were within the defined applicability domain of the developed QSAR model. Predicted BMD concentrations for PPARα activation were in the range between 0.3 µM and 420 µM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.